5 completed. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
Follow KD025: new trials by email Literature Review of KD025 trials Research Report on KD025
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment KD025 - Hepatic Impairment | Phase 1 | Completed | Kadmon, a Sanofi Company | 35 | 2019-12-11 | 2022-07-18 |
| Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 Belumosudil 200 mg tablet, [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose, [14C]-KD025 200 mg capsule - Autoimmune Diseases, Fibrosis | Phase 1 | Completed | Kadmon Corporation, LLC | 5 | 2019-04-05 | 2022-05-26 |
| A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer) | Phase 1 | Completed | Kadmon, a Sanofi Company | 8 | 2014-03-28 | 2023-06-26 |
| A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer) | Phase 1 | Completed | Kadmon, a Sanofi Company | 32 | 2013-11-21 | 2023-06-26 |
| A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer) | Phase 1 | Completed | Kadmon, a Sanofi Company | 32 | 2009-09-21 | 2023-06-26 |
Immune System Diseases (3) · Autoimmune Diseases (1) · Fibrosis (1)
Kadmon, a Sanofi Company (4) · Kadmon Corporation, LLC (1)
United States (4) · United Kingdom (1)
2018 (1)